Tag Archives: ViiV Healthcare

July, 2018

26 July
Studies Show Two-Drug Regimen of Dolutegravir and Lamivudine Has Similar Efficacy to a Three-Drug Regimen in Treatment Naïve HIV Patients

LONDON–(BUSINESS WIRE)–ViiV Healthcare today presented at the 22nd International AIDS conference in Amsterdam 48-week results from the phase III GEMINI 1 & 2 studies, assessing the safety and efficacy of a two-drug regimen (2DR) of dolutegravir (DTG) and lamivudine (3TC) compared to a three-drug regimen of dolutegravir and two nucleoside …
Share

27 November
FDA Approves ViiV Healthcare’s Juluca for Treatment of Patients with HIV

London, 21 November 2017 – ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) has approved Juluca®, indicated as a complete regimen for the maintenance treatment of HIV-1 infection in adults who …
Share

10 June
ViiV Announces FDA Approval to Lower the Weight Limit for Dolutegravir in Children with HIV

LONDON, June 10, 2016 /PRNewswire/ — Reduction of weight limit to at least 30kg means more children and adolescents will be eligible for dolutegravir ViiV Healthcare today announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for dolutegravir 10mg and 25mg oral …
Share

8 January
Viiv and Janssen Collaborate to Develop HIV Maintenance Therapy

CORK, Ireland, January 7, 2016 /PRNewswire/ — Results from ongoing phase IIb Week 32 study show that if successfully developed and approved, people living with HIV could potentially maintain viral suppression Janssen Sciences Ireland UC (Janssen), today formalized its collaboration with ViiV Healthcare on phase III development and commercialization of …
Share

18 December
GSK to Pay up to $1.5 Billion for Next Generation of HIV Treatments

GlaxoSmithKline plc (LSE: GSK) today announced that its global HIV business, ViiV Healthcare, has reached two separate agreements with Bristol-Myers Squibb, to acquire its late-stage HIV R&D assets; and to acquire Bristol-Myers Squibb’s portfolio of preclinical and discovery stage HIV research assets. Under the terms agreed in the two transactions, …
Share

4 November
ViiV Announces Positive Mid-Stage Results for its HIV Therapy

London, UK, 3 November 2015 – ViiV Healthcare, a global specialist HIV company with GSK, Pfizer Inc. and Shionogi Limited as shareholders, today announced that the Phase IIb study LATTE 2 (NCT02120352) met its primary endpoint at 32 weeks. These results show that the investigational, long acting, injectable formulations of …
Share